Year: 2025
Type: review
Abstract: Drug-drug interactions (DDIs) represent a significant concern for clinical care and public health, but the health consequences of many DDIs remain largely underexplored. This knowledge gap underscores the critical need for pharmacoepidemiologic research to evaluate real-world health outcomes of DDIs. In this review, we summarize the definitions commonly used in pharmacoepidemiologic DDI studies, discuss common sources of bias, and illustrate through examples how these biases can be mitigated.
DOI: 10.1002/pds.70088
Language: English
Subfield: Geriatrics and Gerontology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Deutsche Forschungsgemeinschaft, Irish Research Council, Novo Nordisk, National Institutes of Health, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke
Awards: G101110382, U.S. Deprescribing Research Network, Leveraging a Natural Experiment to Determine the Effects of Integrated Palliative Care on Health Service Outcomes and Disparities in Parkinson Disease and Lewy Body Dementia, Drug-Drug Interactions Involving Methadone and Buprenorphine, STIMULANT OVERDOSE IN THE MEDICAID POPULATION: WHO IS AT RISK, AND WHEN ARE THEY AT RISK, G4804632312, Impact of Anticholinergic and Dopamine Receptor Blocking Drug Exposure on Parkinson Disease Trajectory and Outcomes, G6152596402, Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest, Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacy, Drug interactions involving psychoactive drugs, Drug-drug interactions and kidney disease in hospitalized patients
OpenAlex ID: W4406319754